Andrew N Schiff insider trades: Aclaris Therapeutics (ACRS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
and 13 more companies
Open-market buys and sales
40 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 14, 2022 | ACRS | ↓ Sell | 53,926 | $17.05 | $920K | By Aisling Capital IV LP | Nov 14, 2022 (0d) |
| Oct 26, 2022 | ACRS | ↓ Sell | 41,174 | $17.01 | $700K | By Aisling Capital IV LP | Oct 26, 2022 (0d) |
| Oct 18, 2022 | ACRS | ↓ Sell | 52,037 | $16.57 | $862K | By Aisling Capital IV LP | Oct 19, 2022 (1d) |
| Oct 7, 2022 | ACRS | ↓ Sell | 7,324 | $16.16 | $118K | By Aisling Capital IV LP | Oct 11, 2022 (4d) |
| Oct 6, 2022 | ACRS | ↓ Sell | 45,539 | $16.45 | $749K | By Aisling Capital IV LP | Oct 6, 2022 (0d) |
| Jun 17, 2022 | ACRS | ↓ Sell | 19,565 | $15.14 | $296K | Direct | Jun 21, 2022 (4d) |
| Jun 29, 2021 | ELEV | ↑ Buy | 187,500 | $16.00 | $3.0M | Direct | Jul 1, 2021 (2d) |
| Jul 15, 2019 | SNSS | ↑ Buy | 2,500,000 | $0.60 | $1.5M | Indirect | Jul 15, 2019 (0d) |
| Jul 10, 2018 | LOXO | ↓ Sell | 1,400,000 | $179.43 | $251.2M | Direct | Jul 12, 2018 (2d) |
| Dec 19, 2017 | LOXO | ↓ Sell | 250,000 | $80.50 | $20.1M | Direct | Dec 20, 2017 (1d) |
| Nov 22, 2017 | LOXO | ↓ Sell | 500,000 | $75.00 | $37.5M | Direct | Nov 27, 2017 (5d) |
| Aug 16, 2017 | ACRS | ↑ Buy | 108,601 | $23.02 | $2.5M | By Aisling Capital IV LP | Aug 16, 2017 (0d) |
| Jan 10, 2017 | LOXO | ↑ Buy | 160,000 | $31.00 | $5.0M | Direct | Jan 12, 2017 (2d) |
| Aug 11, 2016 | ZLTQ | ↓ Sell | 500,000 | $36.39 | $18.2M | By Aisling Capital III, L.P. | Aug 12, 2016 (1d) |
| Jul 6, 2016 | SYRS | ↑ Buy | 400,000 | $12.50 | $5.0M | Direct | Jul 6, 2016 (0d) |
| May 17, 2016 | LOXO | ↑ Buy | 232,558 | $21.50 | $5.0M | Direct | May 19, 2016 (2d) |
| Dec 11, 2015 | LOXO | ↑ Buy | 200 | $27.50 | $6K | Direct | Dec 15, 2015 (4d) |
| Dec 9, 2015 | TTOO | ↑ Buy | 307,692 | $9.75 | $3.0M | Indirect | Dec 9, 2015 (0d) |
| Dec 8, 2015 | ZLTQ | ↓ Sell | 32,782 | $30.13 | $988K | Direct | Dec 9, 2015 (1d) |
| Nov 23, 2015 | ZLTQ | ↓ Sell | 255,992 | $30.73 | $7.9M | By Aisling Capital III, LP | Nov 24, 2015 (1d) |
| Nov 19, 2015 | ZLTQ | ↓ Sell | 244,008 | $30.77 | $7.5M | By Aisling Capital III, LP | Nov 20, 2015 (1d) |
| Nov 17, 2015 | LOXO | ↑ Buy | 265,000 | $26.50 | $7.0M | Direct | Nov 19, 2015 (2d) |
| Nov 13, 2015 | LOXO | ↑ Buy | 78,669 | $27.65 | $2.2M | Direct | Nov 16, 2015 (3d) |
| Apr 24, 2015 | ESPR | ↓ Sell | 67,469 | $106.26 | $7.2M | By Aisling Capital II, LP | Apr 27, 2015 (3d) |
| Apr 23, 2015 | ESPR | ↓ Sell | 150,000 | $109.10 | $16.4M | By Aisling Capital II, L.P. | Apr 27, 2015 (4d) |
| Jan 27, 2015 | VSAR | ↑ Buy | 145,000 | $17.25 | $2.5M | See FN | Jan 29, 2015 (2d) |
| Jan 23, 2015 | AGRX | ↑ Buy | 811,966 | $5.85 | $4.8M | See FN | Jan 27, 2015 (4d) |
| Sep 2, 2014 | ZLTQ | ↓ Sell | 35,165 | $22.55 | $793K | Direct | Sep 4, 2014 (2d) |
| Aug 12, 2014 | TTOO | ↑ Buy | 454,545 | $11.00 | $5.0M | Indirect | Aug 14, 2014 (2d) |
| Aug 6, 2014 | LOXO | ↑ Buy | 413,077 | $13.00 | $5.4M | Direct | Aug 6, 2014 (0d) |
| May 23, 2014 | AGRX | ↑ Buy | 1,333,333 | $6.00 | $8.0M | By Aisling Capital III, LP | May 28, 2014 (5d) |
| Apr 21, 2014 | TRXC | ↑ Buy | 1,037,767 | $4.00 | $4.2M | By Aisling Capital III, LP | Apr 23, 2014 (2d) |
| Mar 26, 2014 | VSAR | ↑ Buy | 60,000 | $21.00 | $1.3M | See FN | Mar 27, 2014 (1d) |
| Mar 21, 2014 | DRTX | ↓ Sell | 100,649 | $15.74 | $1.6M | By Aisling Capital III, LP | Mar 21, 2014 (0d) |
| Nov 14, 2013 | ZLTQ | ↓ Sell | 575,000 | $12.22 | $7.0M | By Aisling Capital III, LP | Nov 15, 2013 (1d) |
| Oct 22, 2013 | ADMA | ↑ Buy | 411,765 | $8.50 | $3.5M | By Aisling Capital II, LP | Oct 23, 2013 (1d) |
| Jul 1, 2013 | ESPR | ↑ Buy | 238,119 | $14.00 | $3.3M | By Aisling Capital II, L.P. | Jul 1, 2013 (0d) |
| Jul 24, 2012 | DRTX | ↑ Buy | 1,111,111 | $9.00 | $10.0M | By Aisling Capital III, LP | Jul 25, 2012 (1d) |
| Feb 7, 2012 | CEMP | ↑ Buy | 1,213,663 | $6.00 | $7.3M | By Aisling Capital II, LP | Feb 9, 2012 (2d) |
| Oct 24, 2011 | ZLTQ | ↑ Buy | 769,231 | $13.00 | $10.0M | Indirect | Oct 25, 2011 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACRS insiders
Open-market trades in the last 12 months
About Andrew N Schiff's insider trades
Andrew N Schiff is an insider at Aclaris Therapeutics (ACRS). Since Oct 24, 2011, Andrew has reported 22 open-market purchases worth $99.3M and 18 sales worth $380.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (30 filings), option exercises (9 filings), conversions (8 filings), other transactions (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.